Clinical Trial Update: Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating capecitabine, temozolomide, and bevacizumab for metastatic or unresectable pancreatic neuroendocrine tumors has completed; results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrinoma
• Glucagonoma
• Pancreatic Cancer
• Pancreatic Neuroendocrine Tumor
• Somatostatinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Shaheen Shagufta | Conditions: Gastrinoma, Glucagonoma | Phase 2 | Status: COMPLETED | Results posted: 2020-12-30